That’s right, the company is not walking away from DMD, it just won’t be the lead programme. If they can seriously outperform the competition then they will be open to partnership. It’s worth going back to the matrix to understand the range of technologies, diseases and tissue targets that the company has in its sights. I’ve seen the matrix several times and have been looking at it as a progress chart, when in fact it is a statement of scalability - the company is definitely not a one hit wonder. The challenge seems to be which one rather than can we.
Ann: AGM Company Presentation, page-50
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.005(2.70%) |
Mkt cap ! $886.5M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 19.0¢ | 17.5¢ | $508.8K | 2.763M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 118941 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 183634 | 2 |
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| PYC (ASX) Chart |
Day chart unavailable